Connect Biopharma Holdings Limited (CNTB) Key Metrics
CNTB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $57.1M
- Enterprise value
- $36.2M
- P/E (TTM)
- —
- Forward P/E
- 0.8
- PEG ratio
- —
- Price / sales
- 19.3
- Price / book
- 2.5 10-yr median 0.8
- EV / EBITDA
- 0.2
- Dividend yield
- —
- Beta
- −0.18
CNTB key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCNTB valuation Price multiples at each fiscal year-end price.
CNTB returns How much profit the business earns on the capital it uses.
CNTB per-share figures Results divided by the shares outstanding at year-end.
CNTB financial health Debt, liquidity and how easily interest is covered.
CNTB efficiency & capital use Working capital cycle and where the cash goes.
CNTB valuation history
CNTB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CNTB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CNTB price vs earnings per share
CNTB key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $157.0M | $76.2M | $65.0M |
| Enterprise value | $113.3M | −$17.3M | −$52.9M |
| Price / sales | — | 2.9 | — |
| Price / book | 3.7 | 0.8 | 0.6 |
| EV / sales | — | -0.7 | — |
| Earnings yield | −35.3% | −20.5% | −95.6% |
| Free cash flow yield | −32.9% | −32.0% | −74.2% |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% |
| Share price at fiscal year-end | $2.82 | $1.38 | $1.18 |
| Per share | |||
| Revenue per share | $0.00 | $0.47 | $0.00 |
| Earnings per share | −$1.00 | −$0.28 | −$1.13 |
| Operating cash flow per share | −$0.92 | −$0.43 | −$0.87 |
| Free cash flow per share | −$0.93 | −$0.44 | −$0.88 |
| Cash per share | $0.80 | $1.70 | $2.15 |
| Book value per share | $0.75 | $1.67 | $1.84 |
| Tangible book value per share | $0.75 | $1.67 | $1.84 |
| Capex per share | $0.01 | $0.01 | $0.01 |
| Debt per share | $0.01 | $0.00 | $0.01 |
| Shares outstanding | 55.7M | 55.2M | 55.1M |
| Change in shares outstanding | +0.8% | +0.3% | — |
| Returns & profitability | |||
| Return on equity (ROE) | −82.7% | −16.1% | −61.2% |
| Return on assets (ROA) | −70.5% | −13.7% | −48.8% |
| Return on tangible assets | −99.0% | −15.4% | −48.8% |
| Free cash flow margin | — | −93.6% | — |
| Financial health | |||
| Total debt | $690,000 | $178,000 | $465,000 |
| Cash & short-term investments | $44.3M | $93.7M | $118.3M |
| Net debt | −$43.7M | −$93.5M | −$117.8M |
| Debt / equity | 0.02 | 0.00 | 0.00 |
| Debt / assets | 0.01 | 0.00 | 0.00 |
| Current ratio | 3.74 | 11.46 | 4.85 |
| Quick ratio | 3.74 | 11.46 | 5.40 |
| Working capital | $37.3M | $88.5M | $97.3M |
| Invested capital | −$1.7M | −$1.4M | −$16.3M |
| Tangible asset value | $41.9M | $92.1M | $101.4M |
| Net current asset value | $36.8M | $87.8M | $96.7M |
| Graham net-net per share | $0.55 | $1.55 | $1.56 |
| Capital allocation | |||
| Share buybacks (net) | — | — | $0 |
| Capex / revenue | 678.1% | 2.9% | — |
| Capex / depreciation | 0.62 | 1.14 | 0.41 |
| Stock-based compensation / revenue | 5,821.9% | 25.8% | — |
| R&D / revenue | 59,059.4% | 112.4% | — |
| SG&A / revenue | 31,781.2% | 73.9% | — |
| Efficiency | |||
| Days sales outstanding | 3,456.1 | 9.8 | — |
| Days of inventory on hand | — | — | -5,153.9 |
| Days payables outstanding | — | 705.4 | 816.1 |
| Cash conversion cycle (days) | — | -695.6 | — |
| Receivables turnover | 0.11 | 37.14 | 0.00 |
| Payables turnover | 0.00 | 0.52 | 0.45 |
| Asset turnover | 0.00 | 0.23 | 0.00 |
| Average receivables | $606,000 | $701,000 | $351,000 |
| Average payables | $1.2M | $1.3M | $2.2M |
| Average inventory | — | — | −$14.0M |
| Intangibles / total assets | 0.1% | 0.1% | 0.0% |
Computed from CNTB's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CNTB valuation and financial ratios
Connect Biopharma earned a return on equity of −82.7% in fiscal 2025. It ended the year with $0.7 million of debt and $44.3 million in cash and short-term investments, a net cash position of $43.7 million.
See the CNTB income statement, the CNTB chart for price history, or the CNTB stock overview for the latest quote and news.
CNTB key metrics FAQ
What is Connect Biopharma's return on equity?
Connect Biopharma's return on equity (ROE) was −82.7% in fiscal 2025: net income of -$55.5 million on average shareholders' equity of $67.1 million.
How much debt does Connect Biopharma have?
Connect Biopharma had total debt of $0.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Connect Biopharma's free cash flow yield?
Connect Biopharma generated -$51.6 million of free cash flow in fiscal 2025, a free cash flow yield of −32.9% on its market value at year-end ($157.0 million).
What is Connect Biopharma's current ratio?
Connect Biopharma's current ratio was 3.74 at the end of fiscal 2025: current assets were 3.74 times current liabilities.